










Aging is a complex process associated with 
accumulation of damage, loss of function and increased 
vulnerability to disease, leading ultimately to death.   
Despite the complicated etiology of aging, an important 
discovery of recent years has been that simple genetic 
alterations can cause a substantial increase in healthy 
lifespan in laboratory model organisms [1].  Many of 
these longevity-extending mutations down-regulate the 
activity of the mTOR/S6K pathway [2-5] suggesting 
that reduced Tor/S6K signaling promotes entry into 
alternative phases normally entered during periods of 
starvation. In fact, dietary restriction (DR), a reduction 
in food intake without malnutrition, lowers Tor/S6K 
signaling and extends the average and maximum life 
span of a variety of organisms including yeast, flies, 
worms, fish, and rodents [1]. In both rodents and 
monkeys, it delays loss of function and reduces the 
incidence of major diseases [1] and in humans it causes 
a reduction in several metabolic factors and markers of 
diseases associated with including diabetes, and 
cardiovascular disease and cancer [6]. In yeast, down-
regulation of the Tor/S6 pathway was shown to be 
important for the effects of DR on longevity and stress 
resistance [7].  
 
Recently, it has been demonstrated that supplementation 
with rapamycin (an inhibitor of mTOR) started both at 9 
and 20 months of life determines a small but significant 
extension of average and maximal life span in 
genetically heterogeneous male and female mice [8, 9]. 
However, in these studies rapamycin supplementation 
did not change the distribution of causes of death, and 
in particular did not reduced cancer. Interestingly, in 
recent issue of Cell Cycle Anisimov and et al. reported 
that lifelong intermittent administration (three times a 
week for 2 weeks, followed by a 2 week break) of 
rapamycin started at 2 mos of age significantly 
increased maximal lifespan and delayed spontaneous 
cancer in normal inbread female 129/Sv mice [10]. This 
study is in agreement with the effect of inhibition of 
Tor/S6K signaling in protecting yeast against age-
dependent DNA mutations [11] and of mutations in GH 
or GHR in reducing cancer incidence in mice and 
humans  [1,  12].   Similarly,  DR  without  malnutrition  
 
 









extends lifespan and powerfully protects against cancer 
in mice [13]. 
 
Rapamycin is an immunosuppressant and 
antiproliferative agent that is clinically used to prevent 
rejection in organ transplantation, primarily in renal 
transplant patients. Rapamycin by inhibiting the 
activation of mTORC1, inhibits effector T-cell 
proliferation and dendritic cell maturation, but does not 
supress TReg cells induction [14]. Data from 
experimental studies indicate that rapamacyin prolongs 
allograft survival and reverses acute rejection of kidney 
allografts in in rodents and humans [15]. Besides the 
well-known immunosuppressive and anti-rejection 
properties of rapamycin, there is accumulating scientific 
evidence supporting a potential anti-atherogenic, anti-
fibrotic, antiangiogenic, and anticancer effect of 
rapamycin [16]. Nevertheless, chronic subministration 
of rapamycin is associated with a number of side effects 
in some renal transplant patients, including impaired 
wound-healing, lymphoceles, delayed graft function, 
anemia, pneumonitis, hypercholesterolemia and 
proteinuria [15, 16]. However, these side effects are 
dose-dependent, and it is not known if lower doses and 
intermittent subministration may limit some of these 
effects and potentiate the beneficial effects. 
Interestingly in this paper rapamycin was able to extend 
lifespan and reduce cancer risk in mice also when used 
with an intermittent schedule. More studies are needed 
to understand benefits and side-effects of rapamycin 
supplementation in different strains of mice and in 
monkeys as a candidate cancer-preventive and life-
extension pharmacological agent. However, the efficacy 
of intermittent rapamycin treatment in cancer 
prevention and life span extension shown by Anisimov 
et al. is very promising since it is likely to reduce the 
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